Microdose Semaglutide Guide: Maintenance Doses, Protocols, and Evidence

What "Microdose" Actually Means in Practice

Semaglutide for weight loss is dosed in a defined titration schedule — 0.25 mg weekly for four weeks, escalating monthly to 0.5, 1.0, 1.7, and finally 2.4 mg weekly (the "maintenance" dose for active weight loss under the Wegovy label). For type 2 diabetes (Ozempic), the titration ends at 2.0 mg weekly.

"Microdose" in the post-loss maintenance context typically means dropping below the titration ceiling once weight goals are reached. The most common patterns clinicians and patient communities describe:

The 0.25 mg weekly dose has the largest community of practice behind it for two reasons. First, it is the standard starting dose for any patient titrating up — the FDA has formally evaluated safety at this dose level, even if not for indefinite-duration use. Second, the standard pen-injector device delivers 0.25 mg as a single click, making it operationally simple. Lower doses (0.1, 0.15) require compounded preparations or partial-pen techniques that introduce variability.

The Honest Evidence Picture

This section deserves a clear-eyed look because it is the most-misrepresented part of the microdose conversation.

What We Have

• Full-dose efficacy data across STEP and SUSTAIN trial programs (semaglutide for weight loss and diabetes, respectively).
• STEP-4 extension data showing that stopping semaglutide leads to substantial regain — the comparison that motivates microdose strategy.
• Pharmacokinetic data showing semaglutide has a half-life around seven days, supporting weekly dosing at any concentration.
• Observational data from clinical practice — patient surveys, prescriber case series, large telehealth platform data — suggesting microdose maintenance preserves a substantial portion of loss with fewer side effects.

What We Don't Have

• Randomized maintenance trials at sub-therapeutic doses. Nobody has run a controlled study comparing microdose semaglutide to placebo over 12+ months in patients post-loss.
• Long-term safety data specifically at sub-therapeutic doses. The full-dose cardiovascular outcome trials cover safety at 2.4 mg, not 0.25 mg, even if extrapolation makes the lower dose look reassuring.
• Optimal-dose definition. We don't know whether 0.25, 0.4, or 0.5 mg weekly is optimal for any given patient profile. Current practice is empirical titration.
• Stopping criteria. There is no validated framework for when (if ever) to taper off microdose maintenance.

Who Is a Candidate for Microdose Maintenance

The patients most likely to benefit from a maintenance microdose share several profile features. None are formal eligibility criteria — these are the patterns that emerge from prescriber experience.

Strong Candidates

• Lost ≥10% body weight on full-dose semaglutide
• Tolerated full dose well, with side effects manageable rather than disabling
• Have built behavioral infrastructure (protein, training, sleep, eating patterns) during loss phase
• Cannot continue full dose due to cost, but want to preserve loss
• Want to avoid the regain trajectory documented in STEP-4
• Have access to a prescriber who is willing to manage off-label dosing

Weaker Candidates

• Significant side effects even at full dose (microdose may help but underlying intolerance suggests caution)
• Pregnancy or active fertility goals
• History of pancreatitis, severe gastroparesis, or specific GI conditions
• Personal or family history of medullary thyroid carcinoma or MEN2
• No prior loss on semaglutide — microdose initiation is not a substitute for proper titration in patients new to GLP-1 therapy

Common Microdose Protocols

The protocols below reflect typical clinical practice as documented across endocrinology, obesity medicine, and telehealth weight-loss platforms in 2026. They are not standardized; specific dose, schedule, and monitoring should always be guided by a prescriber.

Protocol A: Standard Step-Down (Most Common)

1. Stable on full dose (2.4 or 2.0 mg) for at least 3 months
2. Drop to 1.7 mg weekly for 4 weeks; assess weight stability
3. Drop to 1.0 mg weekly for 4 weeks; assess
4. Drop to 0.5 mg weekly for 4 weeks; assess
5. Drop to 0.25 mg weekly indefinitely; weekly weight monitoring
6. Re-escalate one step if 5% regain over 3 months

Protocol B: Aggressive Step-Down (For Cost-Constrained Patients)

1. Stable on full dose for at least 3 months
2. Drop directly to 0.5 mg weekly; 8 weeks observation
3. Drop to 0.25 mg weekly if weight stable
4. Re-escalate trigger remains 5% regain over 3 months

Protocol C: Spaced Dosing (Less Common)

1. Reach 0.5 mg weekly
2. Extend dosing interval to every 10 days
3. Extend to every 14 days if weight remains stable
4. Returns dosing to every 7–10 days on regain

Protocol C is the most controversial — extending the interval may produce trough periods where appetite control fades, particularly in the second week post-injection. Patients reporting good results on this approach typically have very high adherence to the underlying behavioral protocol.

Lab Work and Monitoring

Microdose maintenance is a long-term clinical relationship, not a one-time prescription. Monitoring should include:

Baseline (Before Maintenance Microdose)

• Comprehensive metabolic panel
• Lipid panel
• HbA1c and fasting glucose
• Lipase (if not recent)
• TSH
• Pregnancy test if applicable
• Body composition (DEXA preferred; bioimpedance acceptable)

During Maintenance

• Weight: weekly self-monitoring; quarterly clinic checks
• HbA1c: every 6 months
• Lipid panel: annually
• Body composition: every 6 months if access permits
• Side-effect symptom log: ongoing patient-driven

Re-Escalation Triggers

• 5% regain over any 3-month window
• Significant return of pre-treatment appetite drive (subjective but real)
• Worsening of glycemic markers in patients with diabetes
• Body composition shift (loss of lean mass, gain of fat mass) without scale weight change

Side Effect Profile at Microdose

The general experience reported by patients on maintenance microdose:

Common (Most Patients)

• Reduced food intake (the desired effect)
• Mild nausea after injection, typically lasting 1–2 days, decreasing over weeks
• Slightly altered taste preferences (foods that previously appealed less attractive)
• Gradual changes in alcohol response (some patients report decreased tolerance or interest)

Less Common

• Constipation
• Mild fatigue, especially around the injection
• Injection-site reactions
• Mild headache

Rare but Important

• Pancreatitis (very rare; established risk at any dose, not specifically elevated at microdose)
• Gallstone disease (associated with rapid weight loss generally, not microdose specifically)
• Severe persistent nausea/vomiting (warrants prescriber contact)
• Mood or appetite changes that significantly affect daily function

Cost and Sourcing

Microdose semaglutide cost varies dramatically by source. The realistic 2026 picture:

The compounded-pharmacy pathway is in regulatory flux as of 2026. The April 22, 2026 Category 2 removal of certain peptides changed the legal landscape for several compounded GLP-1 preparations. Patients sourcing through compounders should verify the legal pathway their pharmacy is operating under and work with prescribers familiar with the current regulatory state.

Research-Grade Sourcing for Adjuncts

Patients combining microdose semaglutide with adjunct research peptides (5-Amino-1MQ, tesamorelin, CJC-1295/ipamorelin, AOD-9604) should source those compounds from vendors with documented purity. WolveStack receives small affiliate commissions on referrals; this funds our research and writing without affecting editorial evaluation.

The Bottom Line

Microdose semaglutide is a real, increasingly common, and reasonably well-tolerated maintenance strategy. It is also off-label, observational rather than randomized, and dependent on the quality of the underlying behavioral protocol. The patients who do best on it have built infrastructure around the medication, not relied on the medication to do all the work.

For patients planning their post-loss maintenance, microdose semaglutide is one tool among several — others including continued full-dose therapy, DMR (where available), tirzepatide microdose alternative, and adjunct peptides. The right choice depends on cost, side-effect tolerance, glycemic profile, and access. Discuss with a prescriber, document the protocol, monitor consistently, and have a re-escalation plan defined before you need it.

Frequently Asked Questions